DK2718312T3 - Behandling af tilstande forbundet med sepsis - Google Patents

Behandling af tilstande forbundet med sepsis Download PDF

Info

Publication number
DK2718312T3
DK2718312T3 DK12727919.8T DK12727919T DK2718312T3 DK 2718312 T3 DK2718312 T3 DK 2718312T3 DK 12727919 T DK12727919 T DK 12727919T DK 2718312 T3 DK2718312 T3 DK 2718312T3
Authority
DK
Denmark
Prior art keywords
cxcr1
levels
cells
chemokine
expression
Prior art date
Application number
DK12727919.8T
Other languages
English (en)
Inventor
Graham Cotton
Ola Winqvist
Original Assignee
Tla Targeted Immunotherapies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tla Targeted Immunotherapies Ab filed Critical Tla Targeted Immunotherapies Ab
Application granted granted Critical
Publication of DK2718312T3 publication Critical patent/DK2718312T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/522—Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3679—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by absorption
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • External Artificial Organs (AREA)

Claims (4)

1. Bindingsreagens, der kan binde specifikt til kemokin-receptoren CXCR1 til anvendelse ved behandling af sepsis og/eller respiratorisk distress syndrom (RDS), hvor bindingsreagensen er immobiliseret på en fast bærer, der er indeholdt i en aferese-søjle, hvortil der påføres perifert blod fra en patient, således at CXCR1-eksprimerende celler fjernes fra patientens perifere blod.
2. Bindingsreagens til anvendelse ifølge krav 1, hvor: (i) sepsis er et systemisk inflammationssyndrom, eller formålet med behandlingen er at behandle eller forebygge multipelt organdysfunktionssyndrom, eller hvor RDS'et er akut RDS eller sepsis-associeret RDS; og/eller (ii) bindingsreagensen, der kan binde specifikt til CXCR1, er en agonist eller en antagonist af CXCR1; og/eller (iii) bindingsreagensen, der kan binde specifikt til CXCR1, er udvalgt blandt et antistof og et kemokin; og/eller (iv) CXCR1-eksprimerende celler er monocytter, makrofager eller neutrofiler; og/eller (v) patienten er blevet udvalgt til behandling på basis af detektering af en stigning i niveauet af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 i en prøve opnået fra patienten; og/eller (vi) 20-50 % af patientens blod påføres til søjlen i en enkelt behandling.
3. Fremgangsmåde til overvågning af progression af behandlingen ifølge et hvilket som helst af kravene 1 eller 2 omfattende at bestemme a) niveauerne af kemokin-receptor CXCR1-eksprimerende celler b) niveauer af ekspression af CXCR1; og/eller c) niveauer af celler med høj ekspression af CXCR1 i en prøve opnået fra et individ, hvor: (i) høje niveauer af CXCR1-eksprimerende celler, høje niveauer af ekspression af CXCR1 eller høje niveauer af celler med høj ekspression af CXCR1 eller øgede niveauer af CXCR1-eksprimerende celler sammenlignet med en kontrol, øgede niveauer af ekspression af CXCR1 sammenlignet med en kontrol eller øgede niveauer af celler med høj ekspression af CXCR1 sammenlignet med en kontrol indikerer tilstedeværelse eller progression af sepsis; (ii) reducerede niveauer af CXCR1 -eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 kor-relerer med vellykket behandling.
4. Fremgangsmåde ifølge krav 3, hvor: (i) sepsis er et systemisk inflammationssyndrom, eller behandlingen forebygger multipelt organdysfunktionssyndrom, eller hvor RDS'et er akut RDS eller sepsis-associeret RDS; og/eller (ii) prøven er en prøve af perifert blod, eventuelt hvor de CXCR1-eksprimerende celler er neutrofiler; og/eller (iii) højere niveauer af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 korrelerer med mere aktiv sygdom; og/eller (iv) lave niveauer af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 korrelerer med en mangel på aktiv sygdom eller mindre aktiv sygdom; og/eller (v) øgede niveauer af CXCR1-eksprimerende celler, niveauer af ekspression af CXCR1 og/eller niveauer af celler med høj ekspression af CXCR1 indikerer progression af sygdom.
DK12727919.8T 2011-06-13 2012-06-13 Behandling af tilstande forbundet med sepsis DK2718312T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161496352P 2011-06-13 2011-06-13
PCT/GB2012/051354 WO2012172344A2 (en) 2011-06-13 2012-06-13 Treating conditions associated with sepsis

Publications (1)

Publication Number Publication Date
DK2718312T3 true DK2718312T3 (da) 2018-10-15

Family

ID=46317440

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12727919.8T DK2718312T3 (da) 2011-06-13 2012-06-13 Behandling af tilstande forbundet med sepsis

Country Status (4)

Country Link
EP (1) EP2718312B1 (da)
DK (1) DK2718312T3 (da)
ES (1) ES2688081T3 (da)
WO (1) WO2012172344A2 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193597A1 (en) * 2013-05-02 2014-12-04 University Of Vermont And State Agricultural College Leptin for treating systemic inflammatory response syndrome

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002537362A (ja) 1999-02-22 2002-11-05 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ビオチン化ケモカイン抗体複合体
US6723538B2 (en) * 1999-03-11 2004-04-20 Micromet Ag Bispecific antibody and chemokine receptor constructs
US7601692B2 (en) * 2000-11-28 2009-10-13 Compugen Ltd. MCP-1 splice variants and methods of using same
EP1745032B1 (en) * 2004-05-12 2013-07-31 Merck Sharp & Dohme Corp. CXCR1 and CXCR2 chemokine antagonists
DE102005036505A1 (de) * 2004-07-30 2006-06-01 Adexter Gmbh Vorrichtung und Verfahren zum Isolieren von Zellen, Biopartikeln und/oder Molekülen aus Flüssigkeiten mit dem Ziel einer Anwendung zur Behandlung von Krankheiten des Menschen
JP2008519039A (ja) * 2004-11-04 2008-06-05 ニュー イングランド メデカル センター ホスピタルズ インク Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法
SI2021025T1 (sl) * 2006-05-12 2017-02-28 Ith Immune Therapy Holdings Ab Postopek in sredstva za zdravljenje vnetne črevesne bolezni
NO2321351T3 (da) 2008-08-18 2018-03-31
KR101703785B1 (ko) * 2008-09-10 2017-02-07 아이티에이치 임뮨 세라피 홀딩스 에이비 염증 증상의 치료 방법

Also Published As

Publication number Publication date
WO2012172344A3 (en) 2013-03-14
EP2718312A2 (en) 2014-04-16
WO2012172344A2 (en) 2012-12-20
ES2688081T3 (es) 2018-10-30
EP2718312B1 (en) 2018-07-25

Similar Documents

Publication Publication Date Title
US10429385B2 (en) Treating conditions associated with sepsis
EP3693041A1 (en) Treating cancer
EP2718723B1 (en) Diagnosing and treating inflammatory bowel disease and irritable bowel syndrome
DK2718312T3 (da) Behandling af tilstande forbundet med sepsis
WO2012172343A2 (en) Treating primary sclerosing cholangitis
DK2718313T3 (da) Behandling af respiratoriske tilstande
WO2012172336A2 (en) Treating inflammatory skin diseases
WO2012172337A2 (en) Treating cardiovascular disease
EP2718310B1 (en) Treating mental disorders
DK2718311T3 (da) Behandling af multipel sklerose
EP2717940B1 (en) Treating conditions associated with metabolic syndrome
WO2012172345A2 (en) Treating conditions associated with allergy
WO2012172339A2 (en) Treating inflammatory arthritis